RxDoctor Payments Data

Christopher Traughber, MD

Family Medicine · Rancho Palos Verdes, CANPI 1992734701

Payments from drug & device makers

$3,450in general payments, 2019–2025

Across 142 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$502
  • AstraZeneca$408
  • Amgen$315
  • Johnson & Johnson$307
  • Merck$266
  • Amarin Pharma, Inc.$210
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,450 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$95,416
Medicare patients
310
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$97,123
OtezlaApremilast11$52,913
OzempicSemaglutide35$46,712
JanuviaSitagliptin Phosphate31$34,118
FarxigaDapagliflozin Propanediol38$32,213
XareltoRivaroxaban34$31,436
JardianceEmpagliflozin18$24,262
Omega-3 Acid Ethyl Esters80$10,143
Colesevelam Hcl12$7,520
MyrbetriqMirabegron13$6,932
Rosuvastatin Calcium286$5,671
Levothyroxine Sodium319$4,893
Atorvastatin Calcium439$4,605
Wixela InhubFluticasone Propion/Salmeterol12$4,544
Nifedipine ErNifedipine112$4,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$97,12399 claims
AmgenOtezla$315$52,91311 claims
Novo NordiskOzempic$41$46,71235 claims
MerckJanuvia$266$34,11831 claims
AstraZenecaFarxiga$408$32,21338 claims
Johnson & JohnsonXarelto$307$31,43634 claims
Boehringer IngelheimJardiance$195$24,26218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Rancho Palos Verdes

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →